ES557664A0 - Un procedimiento para la sintesis de derivados de imidazol. - Google Patents

Un procedimiento para la sintesis de derivados de imidazol.

Info

Publication number
ES557664A0
ES557664A0 ES557664A ES557664A ES557664A0 ES 557664 A0 ES557664 A0 ES 557664A0 ES 557664 A ES557664 A ES 557664A ES 557664 A ES557664 A ES 557664A ES 557664 A0 ES557664 A0 ES 557664A0
Authority
ES
Spain
Prior art keywords
hydrogen
synthesis
procedure
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES557664A
Other languages
English (en)
Other versions
ES8801216A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Continental Pharma Inc
Original Assignee
Continental Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Continental Pharma Inc filed Critical Continental Pharma Inc
Publication of ES557664A0 publication Critical patent/ES557664A0/es
Publication of ES8801216A1 publication Critical patent/ES8801216A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/35—Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/24—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES557664A 1985-01-28 1987-08-13 Un procedimiento para la sintesis de derivados de imidazol. Expired ES8801216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU85747A LU85747A1 (fr) 1985-01-28 1985-01-28 Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives

Publications (2)

Publication Number Publication Date
ES557664A0 true ES557664A0 (es) 1987-12-16
ES8801216A1 ES8801216A1 (es) 1987-12-16

Family

ID=19730397

Family Applications (3)

Application Number Title Priority Date Filing Date
ES551274A Expired ES8802141A1 (es) 1985-01-28 1986-01-27 Un procedimiento para la sintesis de derivados de imidazol.
ES557664A Expired ES8801216A1 (es) 1985-01-28 1987-08-13 Un procedimiento para la sintesis de derivados de imidazol.
ES557663A Expired ES8900137A1 (es) 1985-01-28 1987-08-13 Un procedimiento para la sintesis de derivados de imidazol.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES551274A Expired ES8802141A1 (es) 1985-01-28 1986-01-27 Un procedimiento para la sintesis de derivados de imidazol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557663A Expired ES8900137A1 (es) 1985-01-28 1987-08-13 Un procedimiento para la sintesis de derivados de imidazol.

Country Status (18)

Country Link
US (1) US4738979A (es)
EP (1) EP0194984B1 (es)
JP (1) JPS61176571A (es)
KR (1) KR890001972B1 (es)
AT (1) ATE51618T1 (es)
AU (1) AU597239B2 (es)
CA (1) CA1273942C (es)
DE (1) DE3670081D1 (es)
DK (1) DK39286A (es)
ES (3) ES8802141A1 (es)
FI (1) FI860369L (es)
GR (1) GR860223B (es)
IE (1) IE860222L (es)
IL (1) IL77717A (es)
LU (1) LU85747A1 (es)
NO (1) NO860285L (es)
PT (1) PT81910B (es)
ZA (1) ZA86596B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85747A1 (fr) * 1985-01-28 1986-08-04 Continental Pharma Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives
US4882343A (en) * 1987-08-28 1989-11-21 G. D. Searle & Co. Biarylalkylimidazole derivatives as anti-depressants
GB2210875B (en) * 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
DE68917897D1 (de) * 1988-12-15 1994-10-06 Texaco Development Corp Verfahren zur Herstellung von Imidazolen.
CA1321751C (en) * 1989-02-21 1993-08-31 Eugene C. Crichlow Mechanism mediating ruminal stasis in ruminal lactic acidosis
GB2229719B (en) * 1989-03-30 1992-04-29 Farmos Oy Novel aromatase inhibiting 4(5)-imidazoles
GB2248058B (en) * 1990-09-21 1994-09-14 Orion Yhtymae Oy Aromatase inhibiting 4(5)-imidazoles
JPH032168A (ja) * 1989-03-30 1991-01-08 Farmos Yhtymae Oy アロマターゼ阻害活性を有する新規な4(5)―イミダゾール
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
GB9012469D0 (en) * 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
DE602004018121D1 (de) * 2003-04-10 2009-01-15 Orion Corp Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
US11827606B2 (en) 2015-11-18 2023-11-28 Spirify Pharma Inc. Phenyl cyclohexanone derivatives and methods of making and using them
WO2017087388A1 (en) 2015-11-18 2017-05-26 Mitchell Woods Pharmaceuticals, Inc. Phenyl cyclohexanone derivatives and methods of making and using them
EP4168385A4 (en) 2020-06-17 2024-07-17 Spirify Pharma Inc. HYDROXYNORKETAMINE ANALOGS, COMPOSITIONS COMPRISING THEM AND METHODS OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2069481B (en) * 1980-02-13 1983-07-27 Farmos Oy Substituted imidazole derivatives
US4281141A (en) * 1980-05-30 1981-07-28 Eli Lilly And Company 3-(Imidazol-4-yl)-2-phenylpropanenitriles
ZA854400B (en) * 1984-06-18 1987-02-25 Lilly Co Eli 4(5)-substituted imidazoles
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
LU85747A1 (fr) * 1985-01-28 1986-08-04 Continental Pharma Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives

Also Published As

Publication number Publication date
DE3670081D1 (de) 1990-05-10
US4738979A (en) 1988-04-19
AU5269686A (en) 1986-07-31
DK39286A (da) 1986-07-29
KR890001972B1 (ko) 1989-06-05
AU597239B2 (en) 1990-05-31
ZA86596B (en) 1986-09-24
CA1273942A (en) 1990-09-11
PT81910A (en) 1986-02-01
ES551274A0 (es) 1988-04-01
IE860222L (en) 1986-07-28
ES8802141A1 (es) 1988-04-01
LU85747A1 (fr) 1986-08-04
ATE51618T1 (de) 1990-04-15
PT81910B (en) 1987-05-13
KR860005794A (ko) 1986-08-13
GR860223B (en) 1986-04-24
ES8900137A1 (es) 1989-01-16
FI860369A0 (fi) 1986-01-27
CA1273942C (en) 1990-09-11
ES8801216A1 (es) 1987-12-16
IL77717A (en) 1990-07-12
NO860285L (no) 1986-07-29
FI860369A7 (fi) 1986-07-29
ES557663A0 (es) 1989-01-16
EP0194984A1 (en) 1986-09-17
DK39286D0 (da) 1986-01-27
FI860369L (fi) 1986-07-29
JPS61176571A (ja) 1986-08-08
EP0194984B1 (en) 1990-04-04

Similar Documents

Publication Publication Date Title
ES557663A0 (es) Un procedimiento para la sintesis de derivados de imidazol.
DE3587126D1 (de) Carbapenem-derivate und sie enthaltende zusammensetzung.
FI850140L (fi) Kemiska foereningar.
ES8801248A1 (es) Un procedimiento para preparar imidazoles sustituidos
ES514267A0 (es) "un procedimiento para la preparacion de derivados de pirrolidina".
SE8403801D0 (sv) Nya bensotiazepiner med kardiovaskuler anvendbarhet, forfarande for framstellning derav och farmaceutiska kompositioner som innehaller dem
NO890440D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
ATE98960T1 (de) 1,8-benzonaphthyridinderivate, ihre herstellung und diese enthaltende zusammensetzungen.
ES8801656A1 (es) Un procedimiento para la preparacion de un compuesto de quinazolinona.
ES556048A0 (es) Un procedimiento para la preparacion de un derivado de tiazolidina.
DK0413278T3 (da) Anvendelse af xanthinderivater mod mavesår
SE8701524L (sv) Nya sulfonamider och deras framstaellningsfoerfarande
SE8100122L (sv) Nya 2-aminometyl-6-halo-fenoler, framstellning derav och farmaceutiska kompositioner innehallande dessa
SE8303410D0 (sv) Benzene derivatives, processes for their preparation and pharmaceutical compositions comprising them
FR2550189B1 (fr) Nouveaux derives acetyleniques possedant une activite d'inhibiteurs d'enzyme, leur preparation et leur application comme medicament
SU1179926A3 (ru) "cпocoб пoлучehия пpoизboдhыx cemиkapбaзидa или иx kиcлotho-aддиtиbhыx coлeй"
ATE87004T1 (de) Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln.